18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study.
This study aims to assess the prognostic value of F-FDG PET and F-Fluorocholine PET in advanced hepatocellular carcinoma patients undergoing sorafenib treatment.
Evaluation of F-FDG and F-Fluorocholine PET/CT scans
Comparative analysis of prognostic information provided by each imaging modality
F-FCH PET/CT does not add prognostic value beyond current methods in this patient population.
Abstract
F-FCH PET/CT does not provide additional prognostic information.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study. | Synapse